Piper Sandler Maintains Neutral on ResMed, Lowers Price Target to $225

Benzinga · 1d ago
Piper Sandler analyst Adam Maeder maintains ResMed (NYSE:RMD) with a Neutral and lowers the price target from $233 to $225.